Gallic acid grafted chitosan coated berberine hydrochloride nanoparticles as well as preparation method and application thereof

Through gallic acid grafting chitosan-containing berberine hydrochloride nanoparticles, the problem of antibiotic resistance and low application efficiency of natural compounds in the treatment of dairy cow mastitis is solved, and a stable and sustained release nano-scale preparation is provided to achieve Effective treatment of cow mastitis.

CN118986936APending Publication Date: 2024-11-22BEIJING UNIV OF AGRI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411103737.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-13
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing antibiotics for the treatment of dairy cow mastitis have problems with drug-resistant strains, and the oral application of natural compounds is inefficient, resulting in a reduced treatment efficiency and a first-pass effect in the liver, affecting the bioavailability of the drug.

Method used

Using gallic acid grafted chitosan-containing berberine hydrochloride nanoparticles, nanoparticles are prepared by ionic gel method, combined with chitosan graft modification and nanoencapsulation technology to form a nano-scale preparation with good stability. Sustained release effect and good antibacterial and antioxidant activities.

Benefits of technology

Overcoming the problems of solubility and dosage form limitations of natural compounds, it provides an effective nano-scale preparation, which has a good inhibitory effect on pathogenic bacteria of cow mastitis, and is safe for cow cells, achieving sustained release and efficient therapeutic effects. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118986936A_ABST
    Figure CN118986936A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of animal husbandry, and provides gallic acid grafted chitosan coated berberine hydrochloride nanoparticles as well as a preparation method and application thereof, according to the method, gallic acid grafted chitosan is taken as a raw material, sodium tripolyphosphate is taken as a cross-linking agent, and the gallic acid grafted chitosan coated berberine hydrochloride nanoparticles are prepared by adopting an ionic gel method. According to the invention, the three natural compounds are organically combined in graft copolymerization and nano encapsulation modes, and the obtained nanoparticles are good in characterization, stable in property, small in particle size and uniform in dispersity. The lactobacillus plantarum has good in-vitro antibacterial ability on dairy cow mastitis pathogenic bacteria, and has good in-vitro antioxidant activity. After berberine hydrochloride is entrapped, the sustained-release effect is shown, and the cell safety is good. According to the invention, the problems that the solubility and dosage forms of chitosan, gallic acid and berberine hydrochloride are limited are solved by combining chitosan graft modification and nano encapsulation technologies, and the nano-scale preparation for treating bacterial cow mastitis is successfully researched and developed.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of animal husbandry, and in particular to gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles and a preparation method and application thereof. Background Art

[0002] Cow mastitis refers to an inflammatory disease of the mammary tissue of cows, which is the most important factor hindering the development of the dairy industry and damaging the health of consumers. The disease is mainly caused by bacterial infection, among which Staphylococcus aureus (S.aureus) and Escherichia coli (E.coli) are the most common. At present, the treatment of mastitis mainly relies on antibiotics. However, this will produce drug-resistant strains, resulting in reduced treatment efficiency. At the same time, there is a problem of antibiotic residues, which seriously affects human health. Therefore, it is urgent to find a natural compound to replace antibiotics. However, a single natural compound is obviously lacking in effectiveness against cow mastitis with complex etiologies. Moreover, the compound is mostly used orally, which will cause the drug to be consumed in advance due to the first-pass effect of the liver, which reduces the bioavailability of the drug to cows to a certain extent. Therefore, providing a new composite natural compound and administration method for the treatment of cow mastitis has become an urgent problem to be solved in the dairy farming industry. Summary of the invention

[0003] The purpose of the present invention is to overcome the defects in the prior art and provide a gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles and a preparation method and application thereof.

[0004] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0005] The present invention provides a method for preparing gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles, comprising the following steps:

[0006] (1) mixing an aqueous solution of acetic acid containing chitosan grafted with gallic acid and berberine hydrochloride to obtain an intermediate system;

[0007] (2) mixing the sodium tripolyphosphate solution and the intermediate system to obtain the gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles.

[0008] Preferably, the concentration of the acetic acid aqueous solution of gallic acid grafted chitosan in step (1) is 1 to 2.5 mg / mL.

[0009] Preferably, the pH of the acetic acid aqueous solution of gallic acid grafted chitosan in step (1) is 4-5.

[0010] Preferably, in step (1), the mass ratio of gallic acid grafted chitosan to berberine hydrochloride is 6 to 6.5:1.

[0011] Preferably, the mixing speed in step (1) is 3000-4000 rpm and the mixing time is 30-40 min.

[0012] Preferably, the concentration of the sodium tripolyphosphate solution in step (2) is 0.5-1.5 mg / mL.

[0013] Preferably, the mass ratio of the gallic acid grafted chitosan to sodium tripolyphosphate is 3-5:1.

[0014] Preferably, the mixing speed in step (2) is 300-400 rpm and the mixing time is 30-40 min.

[0015] The present invention also provides the gallic acid grafted chitosan entrapped berberine hydrochloride nanoparticles prepared by the preparation method of the gallic acid grafted chitosan entrapped berberine hydrochloride nanoparticles.

[0016] The present invention also provides the use of the gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles in the preparation of a drug for preventing and treating dairy cow mastitis and a drug for scavenging free radicals.

[0017] The present invention provides a method for preparing gallic acid grafted chitosan-encapsulated berberine hydrochloride nanoparticles. The method uses gallic acid grafted chitosan as a raw material, sodium tripolyphosphate as a cross-linking agent, and adopts an ion gel method to prepare gallic acid grafted chitosan-encapsulated berberine hydrochloride nanoparticles. The present invention organically combines three natural compounds in the form of graft copolymerization and nanoencapsulation, and the obtained nanoparticles are well characterized, stable in nature, small in particle size, and uniform in dispersion. The nanoparticles have good in vitro antibacterial ability against bovine mastitis pathogens and good in vitro antioxidant activity. After encapsulating berberine hydrochloride, a sustained release effect is exhibited, and cell safety is good.

[0018] The present invention overcomes the solubility and dosage form limitations of chitosan, gallic acid and berberine hydrochloride by combining chitosan grafting modification and nanoencapsulation technology, and successfully develops a nanoscale preparation for treating bacterial bovine mastitis, providing a new idea for the treatment of bovine mastitis. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 This is the infrared spectrum of the gallic acid grafted chitosan loaded berberine hydrochloride nanoparticles prepared in Example 1;

[0020] Figure 2 This is a scanning electron micrograph of the gallic acid grafted chitosan loaded berberine hydrochloride nanoparticles prepared in Example 1;

[0021] Figure 3 This is a sustained release curve of berberine hydrochloride nanoparticles encapsulated by gallic acid grafted chitosan prepared in Example 1;

[0022] Figure 4 This is the antibacterial graph of berberine hydrochloride nanoparticles encapsulated by gallic acid grafted chitosan prepared in Example 1;

[0023] Figure 5 This is a time-inhibition curve of berberine hydrochloride nanoparticles encapsulated by gallic acid grafted chitosan prepared in Example 1;

[0024] Figure 6 This is a scanning electron microscopic image of bacteria co-incubated with gallic acid grafted chitosan loaded with berberine hydrochloride nanoparticles prepared in Example 1;

[0025] Figure 7 This is a graph showing the in vitro scavenging activity of berberine hydrochloride nanoparticles encapsulated with gallic acid grafted chitosan prepared in Example 1 on DPPH free radicals;

[0026] Figure 8 This is a graph showing the in vitro scavenging activity of berberine hydrochloride nanoparticles encapsulated with gallic acid grafted chitosan prepared in Example 1 on hydroxyl radicals;

[0027] Fig. 9 This is a graph showing the effects of different drugs on the survival rate of bovine mammary epithelial cells. DETAILED DESCRIPTION

[0028] The present invention provides a method for preparing gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles, comprising the following steps:

[0029] (1) mixing an aqueous solution of acetic acid containing chitosan grafted with gallic acid and berberine hydrochloride to obtain an intermediate system;

[0030] (2) mixing the sodium tripolyphosphate solution and the intermediate system to obtain the gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles.

[0031] The present invention provides a method for preparing gallic acid grafted chitosan, comprising the following steps:

[0032] Mixing 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloric acid solution, N-hydroxysuccinimide and gallic acid solution to obtain an intermediate system;

[0033] The chitosan solution and the intermediate system are mixed and reacted to obtain the gallic acid grafted chitosan.

[0034] In the present invention, the solvent of the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride solution is 2-(N-morpholine)ethanesulfonic acid buffer; the concentration of the 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride solution is preferably 0.15 to 0.17 g / mL, more preferably 0.155 to 0.165 g / mL, and more preferably 0.158 to 0.162 g / mL.

[0035] In the present invention, the solvent of the gallic acid solution is ethanol; the concentration of the ethanol is preferably 10-50%, more preferably 20-40%, and more preferably 30-35%; the concentration of the gallic acid solution is preferably 0.175-0.18 g / mL, more preferably 0.176-0.179 g / mL, and more preferably 0.177-0.178 g / mL.

[0036] In the present invention, the molar ratio of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide and gallic acid is preferably 4.5-5.5:4.5-5.5:4.5-5.5, more preferably 4.6-5.4:4.6-5.4:4.6-5.4, and more preferably 4.8-5.2:4.8-5.2:4.8-5.2.

[0037] In the present invention, the mixing temperature of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloric acid solution, N-hydroxysuccinimide and gallic acid solution is preferably 0-5°C, more preferably 1-4°C, more preferably 2-3°C; the mixing time is preferably 1-1.5h, more preferably 1.1-1.4h, more preferably 1.2-1.3h.

[0038] In the present invention, the temperature of the chitosan solution is preferably 2 to 6°C, more preferably 2.5 to 5.5°C, and even more preferably 3 to 5°C.

[0039] In the present invention, the solvent of the chitosan solution is glacial acetic acid, and the concentration of the glacial acetic acid is preferably 1 to 1.5%, more preferably 1.1 to 1.4%, and even more preferably 1.2 to 1.3%.

[0040] In the present invention, the concentration of the chitosan solution is preferably 0.004 to 0.0045 g / mL, more preferably 0.0041 to 0.0044 g / mL, and even more preferably 0.0042 to 0.0043 g / mL.

[0041] In the present invention, the molar ratio of chitosan to gallic acid is preferably 0.5-1.5:4.5-5.5, more preferably 0.6-1.4:4.6-5.4, and even more preferably 0.8-1.2:4.8-5.2.

[0042] In the present invention, the mixing temperature of the chitosan solution and the intermediate system is preferably 0-5°C, more preferably 1-4°C, more preferably 2-3°C; the mixing time is preferably 30-60 min, more preferably 35-55 min, more preferably 40-50 min; stirring is maintained during the mixing process.

[0043] In the present invention, the reaction temperature is preferably 20-30°C, more preferably 22-28°C, more preferably 24-26°C; the reaction time is preferably 10-14h, more preferably 10.5-13.5h, more preferably 11-13h.

[0044] In the present invention, after the reaction is completed, ultrapure water is used for dialysis, and the molecular weight of the dialysis is preferably 3000-4000Da, more preferably 3200-3800Da, and more preferably 3500Da; the dialysis time is preferably 65-75h, more preferably 66-74h, and more preferably 68-72h. Gallic acid grafted chitosan is obtained after the dialysis.

[0045] In the present invention, the concentration of the acetic acid aqueous solution of the gallic acid grafted chitosan in step (1) is preferably 1-2.5 mg / mL, more preferably 1.5-2 mg / mL, and even more preferably 1.7-1.8 mg / mL.

[0046] In the present invention, the concentration of the aqueous acetic acid solution is preferably 0.5 to 1.5%, more preferably 0.6 to 1.4%, and even more preferably 0.8 to 1.2%.

[0047] In the present invention, the pH of the acetic acid aqueous solution of the gallic acid grafted chitosan in step (1) is preferably 4-5, more preferably 4.2-4.8, and more preferably 4.4-4.6; the pH is adjusted by sodium hydroxide solution, and the concentration of the sodium hydroxide solution is preferably 0.05-0.15M, more preferably 0.06-0.14M, and more preferably 0.08-0.12M.

[0048] In the present invention, the volume mass ratio of gallic acid grafted chitosan to berberine hydrochloride in step (1) is preferably 6-6.5:1, more preferably 6.1-6.4:1, and more preferably 6.2-6.3:1.

[0049] In the present invention, the mixing speed in step (1) is preferably 3000-4000 rpm, more preferably 3200-3800 rpm, more preferably 3400-3600 rpm; the mixing time is preferably 30-40 min, more preferably 32-38 min, more preferably 34-36 min.

[0050] In the present invention, the concentration of the sodium tripolyphosphate solution in step (2) is preferably 0.5 to 1.5 mg / mL, more preferably 0.6 to 1.4 mg / mL, and more preferably 0.8 to 1.2 mg / mL.

[0051] In the present invention, the sodium tripolyphosphate solution is added dropwise to the intermediate system and then mixed.

[0052] In the present invention, the mass ratio of the gallic acid grafted chitosan to sodium tripolyphosphate is preferably 3-5:1, more preferably 3.5-4.5:1, and more preferably 3.8-4.2:1.

[0053] In the present invention, the mixing speed in step (2) is preferably 300-400 rpm, more preferably 320-380 rpm, more preferably 340-360 rpm; the mixing time is preferably 30-40 min, more preferably 32-38 min, more preferably 34-36 min; the temperature is preferably 20-30°C, more preferably 22-28°C, more preferably 24-26°C.

[0054] The present invention also provides the gallic acid grafted chitosan entrapped berberine hydrochloride nanoparticles prepared by the preparation method of the gallic acid grafted chitosan entrapped berberine hydrochloride nanoparticles.

[0055] The present invention also provides the use of the gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles in the preparation of a drug for preventing and treating dairy cow mastitis and a drug for scavenging free radicals.

[0056] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.

[0057] Example 1

[0058] 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloric acid and 2-(N-morpholine)ethanesulfonic acid buffer were mixed to prepare a solution with a concentration of 0.159 g / mL; gallic acid and ethanol (15%) were mixed to prepare a solution with a concentration of 0.177 g / mL; chitosan was dissolved in glacial acetic acid (1%) to prepare a solution with a concentration of 0.0043 g / mL.

[0059] 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloric acid solution, N-hydroxysuccinimide and gallic acid solution were mixed, wherein the molar ratio of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloric acid, N-hydroxysuccinimide and gallic acid was 1:1:1; the mixture was mixed at 0°C for 1 hour to obtain an intermediate system; the chitosan solution and the intermediate system were mixed, wherein the molar ratio of chitosan and gallic acid was 0.2:1, stirred at 0°C for 30 minutes, and then heated to 25°C for reaction for 12 hours; after the reaction, the chitosan grafted with gallic acid was obtained after dialyzing with ultrapure water for 72 hours (3500Da), which was recorded as GA-g-CS.

[0060] The obtained gallic acid grafted chitosan was dissolved in an acetic acid aqueous solution (concentration of 1%) to obtain a 1.5 mg / mL solution; then the pH was adjusted to 4.5 with a 0.1 M sodium hydroxide solution. Berberine hydrochloride (BBR) was added to the above solution at a mass ratio of 1:6.3 to gallic acid grafted chitosan, and stirred at 3500 rpm for 30 min to obtain an intermediate system; then a 1.5 mg / mL sodium tripolyphosphate (TPP) solution was prepared, and the sodium tripolyphosphate solution was added dropwise to the intermediate system, and the mass ratio of gallic acid grafted chitosan and sodium tripolyphosphate was controlled to be 5:1; stirred at 350 rpm for 30 min at 25°C to obtain gallic acid grafted chitosan encapsulated berberine hydrochloride nanoparticles, recorded as BBR@GA-g-CSNPs.

[0061] The obtained gallic acid grafted chitosan was dissolved in an acetic acid aqueous solution (concentration of 1%) to obtain a 1.5 mg / mL solution; then the pH was adjusted to 4.5 with a 0.1 M sodium hydroxide solution. Then a 1.5 mg / mL sodium tripolyphosphate (TPP) solution was prepared, and the sodium tripolyphosphate solution was added dropwise to the intermediate system, and the mass ratio of gallic acid grafted chitosan and sodium tripolyphosphate was controlled to be 5:1; the mixture was stirred at 350 rpm for 30 min at 25°C to obtain gallic acid grafted chitosan nanoparticles, which were recorded as GA-g-CSNPs.

[0062] The berberine hydrochloride nanoparticles encapsulated by gallic acid grafted chitosan prepared in this example were subjected to infrared scanning, and the results were as follows: Figure 1 As shown, BBR is at 3466 and 3315 cm -1 There are fairly large bands at 2916 and 2845 cm, reflecting the stretching vibrations of NH and OH, respectively. -1 The other bands at 1597, 1103, and 1032 cm -1 The peaks at 1026 cm-1 and 1077 cm-2 correspond to aromatic CC vibration, inward bending of the CH plane, and CH vibration. -1There is a characteristic peak at 3419 cm-1, which is related to the vibration of the pyranose unit. When BBR is combined with chitosan nanoparticles, the OH peak in the spectrum of GA-g-CS shifts from 3419 to 3384 cm-1. -1 However, the CS-g-GA spectrum associated with the amide I peak from 1621–1636 cm -1 ,3429-2881cm -1 The peaks at 20 and 10 shifted to lower wavenumbers (TPP cross-linking), confirming the strong molecular interaction between the phosphate groups of TPP and the amino groups of CS. The corresponding change in wavenumbers indicated the formation of nanoparticles.

[0063] The gallic acid grafted chitosan loaded berberine hydrochloride nanoparticles prepared in this example were observed under a scanning electron microscope. The results are as follows: Figure 2 As shown, uniformly dispersed spherical nanoparticles can be seen in the figure, and the average particle size is 143.2±9.78nm.

[0064] Take 30mL of BBR@GA-g-CSNPs dispersion in a dialysis bag, put it into 100mL of PBS buffer (pH=7.4), place the beaker on a magnetic stirrer, set the temperature to 37°C, the speed to 120rpm / min, and stir continuously. At fixed time intervals (0.25.0.50, 0.75, 1.00, 2.00, 3.00, 4.00, 5.00, 6.00, 8.00, 10.00, 12.00, 24.00, 36.00, 48.00h), take out 1mL of sample and replace the same volume of PBS buffer. Filter the sample taken out through a 0.22μm filter membrane and test the berberine hydrochloride concentration at 254nm by HPLC. The berberine hydrochloride release rate is determined by the following formula:

[0065] Wherein: Et (%) represents the release efficiency; P1 represents the amount of BBR released, and P2 represents the total amount of BBR encapsulated by leuproin nanoparticles.

[0066] The sustained release results are as follows Figure 3 As shown in the figure, it can be seen that the rapid release of BBR in BBR@GA-g-CSNPs (burst effect) was first observed. BBR was released by 86.80±0.82% and 78.36±0.84% ​​in the BBR group and BBR@GA-g-CSNPs group at 8 h, respectively. In the later period, the drug release rate slowed down significantly.

[0067] Antimicrobial activity research performance testing

[0068] Bovine Staphylococcus aureus (S. aureus) ATCC 29740 was purchased from ATCC and Escherichia coli (E. coli) CVCC 1450 was purchased from CVCC.

[0069] Preparation of bacterial suspension

[0070] S. aureus ATCC 29740 and E. coli CVCC 1450 were cultured overnight to the logarithmic growth phase, and the test bacterial solution was diluted 10 times to 10 with sterile broth medium. -5 , 10 -6 , 10 -7 , 10 -8 Then, 10 μL of the diluted bacterial solution in the test tube was dropped onto the surface of the solid culture medium and cultured in a 37°C incubator for 24 h before counting the colonies. Finally, 3 to 6×10 5 CFU / mL and 3~6×10 8 The bacterial solution with CFU / mL was used for subsequent experiments.

[0071] Preparation of BBR@GA-g-CSNPs solution

[0072] The BBR@GA-g-CSNPs prepared in this example were sterilized by high pressure steam at a temperature of 121-126°C and an atmospheric pressure of 104.0-137.3 kPa for 20 min, with an original concentration of 0.08 mg / mL (calculated based on the amount of berberine hydrochloride), and then serially diluted by two times with sterile broth culture medium to obtain sample solutions with concentrations of 0.08, 0.04, 0.02, 0.01, 0.005, and 0.0025 mg / mL.

[0073] Determination of minimum inhibitory concentration and minimum bactericidal concentration

[0074] 100 μL of the prepared test solution of different concentrations was added to the first 10 wells of the 96-well plate, and then the same volume of the test bacterial solution (3-6×10 5CFU / mL), and 200μL bacterial suspension and 200μL broth medium were added to the last two wells as positive and negative controls. The wells were placed in an incubator at 37°C for 24 hours for observation. The last clear well without bacterial growth was the minimum inhibitory concentration. 10μL of the liquid in the clear well was dropped on the solid culture medium. The last well without bacterial growth was the minimum bactericidal concentration. Each group of experiments was repeated 3 times. The results are shown in Table 1. It can be seen from the table that BBR@GA-g-CSNPs have an inhibitory effect on both bovine mastitis pathogens, and the best inhibitory effect is on Gram-positive bacteria S.aureus ATCC 29740, with a MIC of 0.02mg / mL and a MBC of 0.04mg / mL. The inhibitory effect on Gram-negative bacteria E.coli CVCC 1450 is slightly weaker than that on Staphylococcus aureus, with a MIC of 0.04mg / mL and a MBC of 0.08mg / mL.

[0075] Table 1 In vitro antibacterial results of BBR@GA-g-CSNPs

[0076]

[0077] Determination of inhibition zone diameter

[0078] Using the Kirby-Bauer disk diffusion method, 0.20 mL of 1×10 8 The test bacterial suspension with a concentration of CFU / mL was evenly spread on MH(A) medium, and then BBR@GA-g-CSNPs with a concentration of 0.08 mg / mL (calculated according to the amount of berberine hydrochloride) and GA-g-CSNPs and BBR paper with the same concentration were attached. The diameter of the inhibition zone was measured after overnight culture at 37°C for 18 to 24 hours. The results are shown in Figure 2. Figure 4 As shown, Figure 4 The left side is S. aureus (ATCC 29740), and the right side is E. coli (CVCC 1450); the data results are recorded in Table 2. Figure 4 As can be seen from Table 2, from the perspective of the diameter of the inhibition zone, the nanoparticles are more sensitive to S. aureus ATCC 29740 than to E. coli CVCC 1450. The nanoparticles loaded with berberine hydrochloride have stronger antibacterial activity (inhibition zone diameter 14.48 ± 0.45 mm), which verifies the synergistic effect between modified chitosan and berberine hydrochloride.

[0079] Table 2 Diameter of inhibition zone of BBR@GA-g-CSNPs

[0080] S. aureus(mm) E.coli(mm) BBR@GA-g-CSNPs 14.48±0.45 7.01±0.31 GA-g-CSNPs 10.62±0.23 6.77±0.25 BBR 9.23±0.36 6.02±0.33

[0081] Determination of time-inhibition curve

[0082] Take the sample solution with an original concentration of 0.08 mg / mL, set up 1 / 4×MIC, 1 / 2×MIC, 1×MIC and 2×MIC groups, and take 3-6×10 5 The bacterial suspension with CFU / mL was mixed with the drug solution in equal volumes, and cultured in a shaker at 37°C and 120 rpm / min for 24 h. 100 μL was taken out at 0, 2, 4, 6, 12, and 24 h for dilution colony count (refer to the configuration of bacterial suspension). Each group of experiments was repeated 3 times. Figure 5 As shown, a is S.Aureus and b is E.Coli. As can be seen from the figure, compared with the control group, the four concentrations of nanoparticles can inhibit the growth of bovine mastitis pathogens (a: S.aureusATCC 29740, b: E.coli CVCC 1450) to a certain extent, and the greater the concentration, the stronger the ability to inhibit bacterial growth. Within 0 to 24 hours, BBR@GA-g-CSNPs reduced the Lg CFU / mL values ​​of the two bovine mastitis pathogens to varying degrees. The rate of decrease of LgCFU / mL within 6 hours was faster than that within 6 to 24 hours, and the inhibitory effect on S.aureusATCC 29740 was better than that on E.coli CVCC 1450.

[0083] BBR@GA-g-CSNPs and bacteria co-incubation experiment

[0084] Take the sample solution with an original concentration of 0.08 mg / mL, set up 1 / 2×MIC and 1×MIC groups, and take 3-6×10 6 The bacterial solution with CFU / mL was mixed with the drug solution with equal volume. The control group was mixed with the same volume of pure water and cultured in a shaker at 37°C and 120rpm / min for 12h. The solution was centrifuged at 3500rpm / mL at 4, 6, and 12h. The supernatant was discarded and the bacteria were fixed with 2.5% glutaraldehyde solution. After dehydration with 60%, 70%, 80%, 90%, and 100% gradient alcohol, the bacteria were observed for microscopic morphology with SEM. Each group of experiments was repeated 3 times. The results are shown in Figure 6As shown in the figure, it can be seen that the untreated Staphylococcus aureus continued to grow in a normal, regular, uniform and plump state. After being treated with 1 / 2×MIC BBR@GA-g-CSNPs for 4 hours, a rough surface with dents was shown. As time went on, the damage to the bacteria was alleviated to a certain extent, which showed that although the bacteria were inhibited to a certain extent under the incubation of 1 / 2×MIC concentration nanoparticles, the effect gradually weakened with the extension of time. On the other hand, after being treated with 1×MIC BBR@GA-g-CSNPs, some bacteria were broken and deformed, and the cell walls were wrinkled, cracked and even fell off. The damage to the bacteria was more significant than that at low concentrations. As time went on, obvious cell membrane shrinkage and rupture, and cytoplasm overflow could still be observed on the surface of the bacteria. These results are consistent with the above-mentioned time inhibition curve results. The degree of inhibition of the bacteria is controlled by concentration and time, and shows dependence.

[0085] DPPH free radical scavenging assay

[0086] Prepare a 0.4mM DPPH methanol solution, take 200μL and add it to a 96-well plate, then add 50μL of BBR@GA-g-CSNPs solution of different concentrations, add pure water to the blank group, and add GA-g-CSNPs solution and BBR solution to the control group, Vc is a positive control. React at 25℃ in the dark for 30min, and measure the absorbance of the solution at 517nm by UV spectrophotometer. Repeat three times for each sample, and take the average value of the results. The free radical scavenging rate is calculated as follows:

[0087] DPPH free radical scavenging rate = (A DPPH -A 0 ) / A DPPH ×100%

[0088] Where: A DPPH —Absorbance of ethanol solution at 517nm;

[0089] A 0 —Absorbance of BBR@GA-g-CSNPs and control sample solutions at 517 nm.

[0090] The test results are as follows Figure 7 As shown, Vc is the positive control. It can be seen from the figure that the DPPH scavenging ability of BBR@GA-g-CSNPs changes significantly with the increase of concentration in the range of 0.20-0.60 mg / mL; in the range of 0.60-1.00 mg / mL, the DPPH scavenging ability no longer changes significantly, and the clearance rate is 88.02±2.15% when the concentration is 1.00 mg / mL.

[0091] Hydroxyl radical scavenging assay

[0092] Take three 15 mL test tubes and mix 100 μL of different concentrations of BBR@GA-g-CSNPs aqueous solution with 1 mL of 5 μM salicylic acid and ferrous sulfate solution. Add 1 mL of 3 mM H 2 O 2 , pure water was added to the background group, and finally titrated to 10mL with pure water. A blank group was set up with pure water as the test sample, and a control group with GA-g-CSNPs solution and BBR solution as the test samples, respectively. After adding the reaction solution in the above step, it was titrated to 10mL with pure water. The solution was placed at 37°C and reacted in the dark for 20 minutes. The absorbance of the solution was measured at 510nm by an ultraviolet spectrophotometer. Each sample was tested three times, and the results were averaged. The calculation formula for free radical scavenging rate is as follows:

[0093] Hydroxyl radical scavenging rate (%) = [1-(A I -A II / A III )]×100%;

[0094] Where: A I ——Absorbance of BBR@GA-g-CSNPs and control sample solution at 510 nm;

[0095] A II ——Absorbance value of BBR@GA-g-CSNPs and control sample solution without hydrogen peroxide coloration at 510 nm;

[0096] A III ——The absorbance value of pure water at 510nm.

[0097] The test results are as follows Figure 8 As shown, Vc is the positive control. It can be seen from the figure that when the nanoparticle concentration is in the range of 0.20-1.00 mg / mL, the scavenging rate of hydroxyl free radicals increases from 32.26±1.76% to 49.52±2.13%, which is concentration-dependent and reaches the maximum at 1 mg / mL.

[0098] Cell safety test

[0099] Cell culture: Bovine mammary epithelial cells (BMECs) were cultured in DMEM / F-12 (mixed in equal volumes) containing 10% FBS and 1% penicillin-streptomycin. The cells were incubated at 37°C and 5% CO 2 The cells were cultured in an incubator until the logarithmic growth phase. In the experiment, maintenance medium (containing 2% FBS) was used for cell culture.

[0100] Preparation of drug solution: GA-g-CS, GA-g-CSNPs, BBR@GA-g-CSNPs, and BBR prepared in this example were diluted to 5, 10, 50, 100, and 150 μg / mL (calculated based on the amount of grafted chitosan) with complete culture medium.

[0101] 100 μL of drug was added to each well, and different concentrations of drug were incubated with BMECs cells. Different treatment groups were set up for 12 and 24 h. At the same time, a blank group (only culture medium) and a control group (drug concentration was 0) were set up on the 96-well plate. The cells were washed with PBS, and 10 μL of CCK-8 and 90 μL of maintenance culture medium were added to each well. The 96-well plate was placed in a constant temperature incubator (37°C, 5% CO 2 ) for 4 h. The absorbance was measured at 450 nm using an ELISA reader, and the cell viability was calculated according to the following formula.

[0102] Cell viability = (OD 1 -OD 0 ) / (OD 2 -OD 0 )×100%;

[0103] Where: OD 0 is the OD value of the blank group; OD 1 is the OD value of the experimental group; OD 2 is the OD value of the control group.

[0104] The results are as follows Fig. 9 As shown, the cell viability of 5, 10, 50, 100, and 150 μg / mL GA-g-CS, GA-g-CSNPs, BBR@GA-g-CSNPs, and BBR was investigated after incubation with bovine mammary epithelial cells for 12 and 24 h. It can be seen that the above drugs had no cytotoxicity at a concentration less than 50 μg / mL, and the cell viability was higher than 80%. Among them, the cell activity of BBR@GA-g-CSNPs at various concentrations at 12 and 24 h was higher than 100%.

[0105] As can be seen from the above embodiments, the present invention provides a method for preparing gallic acid grafted chitosan-encapsulated berberine hydrochloride nanoparticles, which uses gallic acid grafted chitosan as a raw material, sodium tripolyphosphate as a cross-linking agent, and adopts an ion gel method to prepare gallic acid grafted chitosan-encapsulated berberine hydrochloride nanoparticles. The present invention organically combines three natural compounds in the form of graft copolymerization and nanoencapsulation, and the obtained nanoparticles are well characterized, stable in nature, small in particle size, and uniform in dispersion. It has good in vitro antibacterial ability against bovine mastitis pathogens and good in vitro antioxidant activity. After encapsulating berberine hydrochloride, it shows a sustained release effect and good cell safety.

[0106] The present invention overcomes the solubility and dosage form limitations of chitosan, gallic acid and berberine hydrochloride by combining chitosan grafting modification and nanoencapsulation technology, and successfully develops a nanoscale preparation for treating bacterial bovine mastitis, providing a new idea for the treatment of bovine mastitis.

[0107] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A method for preparing gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles, characterized in that: It includes the following steps: (1) mixing an aqueous solution of acetic acid containing chitosan grafted with gallic acid and berberine hydrochloride to obtain an intermediate system; (2) mixing the sodium tripolyphosphate solution and the intermediate system to obtain the gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles.

2. The method for preparing gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles according to claim 1, characterized in that: The concentration of the acetic acid aqueous solution of gallic acid grafted chitosan in step (1) is 1-2.5 mg / mL.

3. The method for preparing gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles according to claim 1 or 2, characterized in that: The pH of the acetic acid aqueous solution of gallic acid grafted chitosan in step (1) is 4-5.

4. The method for preparing gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles according to claim 3, characterized in that: In step (1), the mass ratio of gallic acid grafted chitosan to berberine hydrochloride is 6 to 6.5:

1.

5. The method for preparing gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles according to claim 1 or 4, characterized in that: The mixing speed in step (1) is 3000-4000 rpm and the mixing time is 30-40 min.

6. The method for preparing gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles according to claim 5, characterized in that: The concentration of the sodium tripolyphosphate solution in step (2) is 0.5-1.5 mg / mL.

7. The method for preparing gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles according to claim 1, 2, 4 or 6, characterized in that: The mass ratio of the gallic acid grafted chitosan to sodium tripolyphosphate is 3-5:

1.

8. The method for preparing gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles according to claim 7, characterized in that: The mixing speed in step (2) is 300-400 rpm and the mixing time is 30-40 min.

9. Gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles prepared by the method for preparing gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles according to any one of claims 1 to 8.

10. Use of the gallic acid grafted chitosan-loaded berberine hydrochloride nanoparticles according to claim 9 in the preparation of a drug for preventing and treating mastitis in dairy cows and a drug for scavenging free radicals.